Abstract
Nonsteroidal anti-inflammatory drugs show chemopreventive efficacy in colon cancer, but the mechanism behind this remains unclear. Elucidating this mechanism is seen as vital to the development of new chemopreventive agents. We studied the effects of aspirin on the oncogenic Wnt/β-catenin pathway activity in colorectal cancer cell lines and observed that aspirin dose-dependently decreased the activity of this pathway, as judged by TCF-driven luciferase activity, reduced Wnt target gene expression and increased phosphorylation of β-catenin by immunoblotting. Furthermore, the ubiquitination and cytoplasmic levels of β-catenin were assessed by immunoblotting, and also the localization of β-catenin was shown by green fluorescent protein-tagged β-catenin and time-lapse fluorescent imaging. Importantly, aspirin treatment caused increased phosphorylation of protein phosphatase 2A (PP2A), an event associated with inhibition of PP2A enzymatic activity, which was confirmed by a reduction in enzymatic PP2A activity. Moreover, this inhibition of PP2A enzymatic activity was essential for the effects of aspirin on the Wnt/β-catenin pathway as shown by transient transfection with PP2A constructs. The findings in this article provide a molecular explanation for the efficacy of aspirin in chemoprevention of colorectal cancer and shows biochemical evidence that PP2A is an important regulator of Wnt/β-catenin pathway activity in these cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE . (2001). Mol Pharmacol 59: 901–908.
Boon EM, van der Neut R, van de Wetering M, Clevers H, Pals ST . (2002). Cancer Res 62: 5126–5128.
Charalambous D, O'Brien PE . (1996). J Gastroenterol Hepatol 11: 307–310.
Chung H, Nairn AC, Murata K, Brautigan DL . (1999). Biochemistry 38: 10371–10376.
Dihlmann S, Klein S, von Knebel Doeberitz M . (2003). Mol Cancer Ther 2: 509–516.
Dihlmann S, Siermann A, von Knebel Doeberitz M . (2001). Oncogene 20: 645–653.
Favre B, Turowski P, Hemmings BA . (1997). J Biol Chem 272: 13856–13863.
Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC et al. (1995). N Engl J Med 333: 609–614.
Green DW, Roh H, Pippin JA, Drebin JA . (2001). J Surg Res 101: 16–20.
Gupta RA, DuBois RN . (1998). Gastroenterology 114: 1095–1098.
Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L et al. (1996). Biochem Pharmacol 52: 237–245.
He TC, Chan TA, Vogelstein B, Kinzler KW . (1999). Cell 99: 335–345.
Husain SS, Szabo IL, Tamawski AS . (2002). Am J Gastroenterol 97: 542–553.
Kishimoto Y, Takata N, Jinnai T, Morisawa T, Shiota G, Kawasaki H et al. (2000). Gut 47: 812–819.
Kitagawa M, Hatakeyama S, Shirane M, Matsumoto M, Ishida N, Hattori K et al. (1999). EMBO J 18: 2401–2410.
Kopp E, Ghosh S . (1994). Science 265: 956–959.
Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C et al. (1991). Gastroenterology 101: 635–639.
Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M et al. (1999). Proc Natl Acad Sci USA 96: 1603–1608.
Marx J . (2001). Science 291: 581–582.
Miller JR, Hocking AM, Brown JD, Moon RT . (1999). Oncogene 18: 7860–7872.
Mistry SJ, Li HC, Atweh GF . (1998). Biochem J 334 (Part 1): 23–29.
Morin PJ . (1999). Bioessays 21: 1021–1030.
Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B et al. (1997). Science 275: 1787–1790.
Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P . (1995). Proc Natl Acad Sci USA 92: 3046–3050.
Nunbhakdi-Craig V, Machleidt T, Ogris E, Bellotto D, White III CL, Sontag E . (2002). J Cell Biol 158: 967–978.
Orena SJ, Torchia AJ, Garofalo RS . (2000). J Biol Chem 275: 15765–15772.
Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW . (1997). J Biol Chem 272: 24735–24738.
Oshima H, Oshima M, Kobayashi M, Tsutsumi M, Taketo MM . (1997). Cancer Res 57: 1644–1649.
Polakis P . (1997). Biochim Biophys Acta 1332: F127–F147.
Ratcliffe MJ, Itoh K, Sokol SY . (2000). J Biol Chem 275: 35680–35683.
Roh H, Green DW, Boswell CB, Pippin JA, Drebin JA . (2001). Cancer Res 61: 6563–6568.
Schonthal AH . (2001). Cancer Lett 170: 1–13.
Seeling JM, Miller JR, Gil R, Moon RT, White R, Virshup DM . (1999). Science 283: 2089–2091.
Seidensticker MJ, Behrens J . (2000). Biochim Biophys Acta 1495: 168–182.
Smal C, Cardoen S, Bertrand L, Delacauw A, Ferrant A, Van den Berghe G et al. (2004). Biochem Pharmacol 68: 95–103.
Smith ML, Hawcroft G, Hull MA . (2000). Eur J Cancer 36: 664–674.
Stark LA, Din FV, Zwacka RM, Dunlop MG . (2001). FASEB J 15: 1273–1275.
Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al. (2000). N Engl J Med 342: 1946–1952.
Tegeder I, Pfeilschifter J, Geisslinger G . (2001). FASEB J 15: 2057–2072.
Thun MJ, Namboodiri MM, Heath Jr CW . (1991). N Engl J Med 325: 1593–1596.
van de Wetering M, Cavallo R, Dooijes D, van Beest M, van Es J, Loureiro J et al. (1997). Cell 88: 789–799.
Xie H, Litersky JM, Hartigan JA, Jope RS, Johnson GV . (1998). Brain Res 798: 173–183.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bos, C., Kodach, L., van den Brink, G. et al. Effect of aspirin on the Wnt/β-catenin pathway is mediated via protein phosphatase 2A. Oncogene 25, 6447–6456 (2006). https://doi.org/10.1038/sj.onc.1209658
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209658
Keywords
This article is cited by
-
Salicylate induces AMPK and inhibits c-MYC to activate a NRF2/ARE/miR-34a/b/c cascade resulting in suppression of colorectal cancer metastasis
Cell Death & Disease (2023)
-
Theoretical basis validation and oxidative stress markers for cancer prevention clinical trials of aspirin
Scientific Reports (2023)
-
Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited
Cellular and Molecular Life Sciences (2022)
-
The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial
BMC Cancer (2020)
-
PP2A and tumor radiotherapy
Hereditas (2020)